Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934606 · ClinicalTrials.gov registry record
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 1,488
- Enrollment target
NCT03934606: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03934606 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,488 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934606 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 1,488 participants
- Enrollment target
Study Summary
To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.
Primary Outcome
Change in distress levels (HADS-Anxiety) from Baseline to Time point #2 (post-disclosure) measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
Interventions
- BEHAVIORAL Genetic testing for hereditary predisposition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,488 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2025-01-31 |
What the finished NCT03934606 record still lists
NCT03934606 is an observational study that tracks outcomes without assigning an intervention. Its 1,488 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Genetic testing for hereditary predisposition is the first listed.
NCT03934606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03934606 about?
NCT03934606 is a clinical study titled "Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model". To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study...
What is the current status of trial NCT03934606?
This trial is currently completed. The enrollment target is 1,488 participants. The study started on 2018-01-01. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT03934606?
The interventions under investigation include: Genetic testing for hereditary predisposition (BEHAVIORAL).
Who is sponsoring clinical trial NCT03934606?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI